Neogen's first fiscal quarter of 2026, ending August 31, 2025, revealed a complex financial landscape, marked by a decline in adjusted net income and earnings per share to $9 million and $0.04, respectively, down from $14 million and $0.07 in the previous year. This reduction was primarily due to a lower adjusted EBITDA, even as interest expenses decreased. The company experienced persistent inefficiencies in sample collection and inventory write-offs, which continued to negatively affect gross margin, despite some sequential improvements. The Food Safety segment's revenue saw a 4.6% decline, including a 1.7% core decrease, with PetriFilm sales dropping by mid-single digits and market share losses observed in key areas like sample collection, allergens, and natural toxins. However, total revenue reached $209 million, reflecting a modest 0.3% core growth, aligning with management's expectations.
In response to these challenges, Neogen is actively implementing a multi-faceted strategy to bolster its financial health and market position. The company initiated a $20 million annualized cost-reduction program at the end of September, including a 10% global workforce reduction and other non-labor cost adjustments, aiming for a $12 million benefit in fiscal 2026. This move is designed to reallocate resources towards critical commercial and research and development initiatives. Furthermore, Neogen completed the sale of its Cleaners and Disinfectants business for $115 million, using $100 million to pay down debt, resulting in $6 million in annualized interest savings. The company is also focused on improving inventory management through enhanced Sales and Operations Planning (SNOP) processes, which are expected to release excess inventory and boost cash generation. Initial product testing for PetriFilm production transfer is underway, with full transition anticipated by the second quarter of the next fiscal year, ensuring supply continuity. Management remains confident in its full-year fiscal 2026 guidance, expecting margin improvements and a sequential revenue increase in the second quarter due to seasonal factors.
Despite previous market share losses attributed to supply and execution issues following the 3M integration, Neogen's leadership, under new CEO Mike Nassif, believes the company can regain ground through improved execution and strategic focus. Nassif emphasized that a major strategic overhaul is unnecessary, and disciplined focus on growth, cost control, and innovation will unlock the company's potential. Efforts to enhance top-line growth include targeted market expansion, pricing adjustments, and organizational changes, such as recruiting a new Chief Commercial Officer. The company aims to strengthen its R&D pipeline in core food safety and animal health categories, prioritizing high-impact projects. Nassif highlighted the ongoing issues in the food industry, such as the persistence of food-borne pathogens and declining consumer confidence, underscoring the critical importance of Neogen's mission to provide world-leading innovation and significantly improve financial performance.
